Date: 2014-06-18
Type of information: Development agreement
Compound:
Company: AstraZeneca (UK) Academic Drug Discovery Consortium - ADDC (USA)
Therapeutic area:
Type agreement:
Action mechanism:
Disease:
Details: * On June 17, 2014, the Academic Drug Discovery Consortium (ADDC) announced a collaboration between ADDC and AstraZeneca aimed at facilitating efforts by researchers from academia and institutions towards the discovery of novel compounds with potential pharmaceutical application. More specifically, the goal of this partnership is to provide ADDC members with access to a high quality compound library, while allowing AstraZeneca the opportunity to collaborate with academic researchers in the hope of identifying novel disease targets and drugs across a wide range of therapy areas. The institutions selected to participate in this project will receive access to up to 250,000 compounds from AstraZeneca\'s internal screening library. The compounds to be made available in this project are intended to provide a broad representation of AstraZeneca\'s compound collection. In order to be considered for this project, candidate institutions must be members of ADDC and respond through a Request for Proposals (RFP) process. Responses will be judged by a Technical Review Committee that will be comprised of representatives from ADDC and AstraZeneca. It is expected that this process will initiate five projects per year, and that the term of the collaboration between the two organizations will be three years, with an option to be renewed. Additional information on this project, eligibility requirements, and the Call for Proposals can be found at http://www.addconsortium.org. Proposals are due August 1, 2014. Proposals selected by the Technical Review Committee will be announced in Fall 2014.
Financial terms:
Latest news:
